Agilent Technologies reported a strong third quarter for fiscal 2026, with revenue up 8.1% year over year to $1.88 billion and earnings per share up 18%. Adjusted earnings per share came in at $1.62, beating the analyst consensus of $1.49 by $0.13, while shares gained more than 3% in premarket trading Thursday. Adjusted EPS included a $0.06 benefit from tariff refunds. Agilent raised its fiscal 2026 adjusted EPS guidance to $6.18-$6.21, with a $6.195 midpoint above the $6.06 analyst consensus, and increased its full-year revenue outlook to $7.49 billion-$7.51 billion, or 7.8%-8.1% growth. The company expects fourth-quarter revenue of $1.98 billion-$2.0 billion and adjusted EPS of $1.71-$1.74. All three business segments posted robust growth, led by the Life Sciences and Diagnostics Markets Group, which reported 11% growth to $746 million. Bank of America analysts said China trends, healthy pharmaceutical demand, ATD and reshoring could support the setup into FY27, while noting uncertainty over how much current momentum will carry forward.